<rdf:RDF xmlns:rdf="http://www.openarchives.org/OAI/2.0/rdf/" xmlns:ow="http://www.ontoweb.org/ontology/1#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:ds="http://dspace.org/ds/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">
   <ow:Publication rdf:about="oai:digibug.ugr.es:10481/82943">
      <dc:title>Patients with severe mental illness and hepatitis C virus infection benefit from new pangenotypic direct-acting antivirals: Results of a literature review</dc:title>
      <dc:creator>Gutiérrez Rojas, Luis</dc:creator>
      <dc:subject>HCV infection</dc:subject>
      <dc:subject>Mental illness</dc:subject>
      <dc:subject>Schizophrenia</dc:subject>
      <dc:subject>Bipolar disorder</dc:subject>
      <dc:subject>Antivirals</dc:subject>
      <dc:date>2023-06-29T10:07:25Z</dc:date>
      <dc:date>2023-06-29T10:07:25Z</dc:date>
      <dc:date>2022-06-17</dc:date>
      <dc:type>journal article</dc:type>
      <dc:identifier>L. Gutiérrez-Rojas, J.J. de la Gándara Martín, L. García Buey et al. Patients with severe mental illness and hepatitis C virus infection benefit from new pangenotypic direct-acting antivirals: Results of a literature review .Gastroenterología y Hepatología 46 (2023) 382---396[https://doi.org/10.1016/j.gastrohep.2022.06.001]</dc:identifier>
      <dc:identifier>https://hdl.handle.net/10481/82943</dc:identifier>
      <dc:identifier>10.1016/j.gastrohep.2022.06.001</dc:identifier>
      <dc:language>eng</dc:language>
      <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
      <dc:rights>open access</dc:rights>
      <dc:rights>Atribución 4.0 Internacional</dc:rights>
      <dc:publisher>Elsevier</dc:publisher>
   </ow:Publication>
</rdf:RDF>